CNP-22 (Human)

<strong>CNP-22 (Human)</strong>_x000D_ <strong>Catalog number:</strong> MDP0614_x000D_ <strong>CAS Number: </strong>131438-79-4_x000D_ <strong>Sequence: </strong>Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bond between Cys6-Cys22)_x000D_ <strong>Amount:</strong> 500 ug_x000D_ <strong>Molecular Weight:</strong> 2197.6 g/mol_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>WARNING:</strong> For in vitro Research Use Only. NOT for use on humans or animals._x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Duggan S. Vosoritide: First Approval Drugs. 2021 Nov;81(17):2057-2062._x000D_ 2: Wrobel W, Pach E, Ben-Skowronek I. Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review Int J Mol Sci. 2021 May 25;22(11):5573._x000D_ 3: Paton DM. Efficacy of vosoritide in the treatment of achondroplasia Drugs Today (Barc). 2022 Sep;58(9):451-456._x000D_ 4: Savarirayan R, Tofts L, Irving M, Wilcox WR, Bacino CA, Hoover-Fong J, Font RU, Harmatz P, Rutsch F, Bober MB, Polgreen LE, Ginebreda I, Mohnike K, Charrow J, Hoernschemeyer D, Ozono K, Alanay Y, Arundel P, Kotani Y, Yasui N, White KK, Saal HM, Leiva-Gea A, Luna-González F, Mochizuki H, Basel D, Porco DM, Jayaram K, Fisheleva E, Huntsman-Labed A, Day JRS. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study Genet Med. 2021 Dec;23(12):2443-2447._x000D_ 5: Chan ML, Qi Y, Larimore K, Cherukuri A, Seid L, Jayaram K, Jeha G, Fisheleva E, Day J, Huntsman-Labed A, Savarirayan R, Irving M, Bacino CA, Hoover-Fong J, Ozono K, Mohnike K, Wilcox WR, Horton WA, Henshaw J. Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia Clin Pharmacokinet. 2022 Feb;61(2):263-280._x000D_ 6: Savarirayan R, Tofts L, Irving M, Wilcox W, Bacino CA, Hoover-Fong J, Ullot Font R, Harmatz P, Rutsch F, Bober MB, Polgreen LE, Ginebreda I, Mohnike K, Charrow J, Hoernschemeyer D, Ozono K, Alanay Y, Arundel P, Kagami S, Yasui N, White KK, Saal HM, Leiva-Gea A, Luna-González F, Mochizuki H, Basel D, Porco DM, Jayaram K, Fisheleva E, Huntsman-Labed A, Day J. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial Lancet. 2020 Sep 5;396(10252):684-692._x000D_ 7: Vosoritide Am J Health Syst Pharm. 2022 Mar 7;79(6):410-412._x000D_ 8: Savarirayan R, Irving M, Bacino CA, Bostwick B, Charrow J, Cormier-Daire V, Le Quan Sang KH, Dickson P, Harmatz P, Phillips J, Owen N, Cherukuri A, Jayaram K, Jeha GS, Larimore K, Chan ML, Huntsman Labed A, Day J, Hoover-Fong J. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia N Engl J Med. 2019 Jul 4;381(1):25-35._x000D_ 9: Perez-Ternero C, Aubdool AA, Makwana R, Sanger GJ, Stimson RH, Chan LF, Moyes AJ, Hobbs AJ. C-type natriuretic peptide is a pivotal regulator of metabolic homeostasis Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2116470119._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32268070">10: Taura D, Nakao K, Nakagawa Y, Kinoshita H, Sone M, Nakao K. C-type natriuretic peptide (CNP)/guanylate cyclase B (GC-B) system and endothelin-1(ET-1)/ET receptor A and B system in human vasculature Can J Physiol Pharmacol. 2020 Sep;98(9):611-617. </a>_x000D_ _x000D_ <strong>Products Related to CNP-22 (Human) can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>